BeBetter Med
- Biotech or pharma, therapeutic R&D
BeBetter Med, founded in 2012 by seasoned U.S. scientists in China, has advanced seven programs into clinical development, including one at the NDA stage. The company is in the final phase of listing on the Shanghai Stock Exchange, pending approval from the China Securities Regulatory Commission (CSRC).
BeBetter Pharma, the U.S. subsidiary of BeBetter Med, leverages proprietary siRNA delivery platforms to accelerate the development of next-generation therapeutics for complex diseases.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}